| EQR |
Report |
Normalized FFO per share |
IN-LINE |
pred ~$1.02 vs. cons $1.01 |
MEDIUM |
| EQR |
Report |
Same-store residential revenue growth |
BEAT |
pred ~3.2% vs. cons 2.7% |
MEDIUM |
| EQR |
Report |
Same-store NOI growth |
BEAT |
pred ~2.3% vs. cons 1.8% |
MEDIUM |
| EQR |
Guide |
Full-year normalized FFO per share guidance |
UNCHANGED |
guide ~$4.08 vs. cons $4.09 (FY2026) |
MEDIUM |
| EQR |
Guide |
Full-year same-store residential revenue growth guidance |
BETTER |
guide ~2.7% vs. cons 2.4% (FY2026) |
MEDIUM |
| EQR |
Guide |
Full-year same-store NOI growth guidance |
BETTER |
guide ~1.8% vs. cons 1.5% (FY2026) |
MEDIUM |
| EQR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.1% |
— |
MEDIUM |
| EQR |
Return |
5-day cumulative residual |
+3.6% (FOLLOW-THROUGH) |
A modest FFO beat is less important than a higher same-store revenue/NOI outlook: implied second-half revenue growth improves to ~3.4% versus prior embedded ~2.8%, supporting ~1.0% to ~1.5% upward FY2026 FFO revisions after the report. |
MEDIUM |